Metastatic Breast Cancer

FDA approves new treatment for certain advanced or metastatic breast cancers (10-5-2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed... Continue Reading

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer (08-30-2017)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast... Continue Reading

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (03-16-2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination... Continue Reading

Keytruda®/Halaven® Combo May Be Effective in Advanced Triple-Negative Breast Cancer (01-9-2017)

The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC) whose disease has advanced following prior... Continue Reading

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer (10-26-2016)

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The... Continue Reading

ASCO Treatment Recommendations for HR+, Metastatic Breast Cancer (09-5-2016)

The American Society of Clinical Oncology (ASCO) recently convened an Expert Panel to create recommendations for endocrine therapy for women with hormone-receptor (HR)-positive, metastatic breast cancer. The panel conducted “a systematic review of evidence... Continue Reading

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer (06-30-2016)

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These... Continue Reading

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study (06-22-2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology... Continue Reading

Abemaciclib Promising in Advanced Breast Cancer (06-7-2016)

The investigative agent abemaciclib, which is still in clinical trials, appears promising in providing anti-cancer activity among patients with metastatic breast cancer that has progressed following several prior therapies. These results were recently... Continue Reading

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (03-28-2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference... Continue Reading

Next Page »